Página 1 dos resultados de 389 itens digitais encontrados em 0.004 segundos

‣ Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation

GOMY, Israel; MOLFETTA, Greice Andreotti; BARRETO, Ester de Andrade; FERREIRA, Cristiane Ayres; ZANETTE, Dalila Luciola; CASALI-DA-ROCHA, Jose Claudio; SILVA JR., Wilson Araujo
Fonte: SPRINGER Publicador: SPRINGER
Tipo: Artigo de Revista Científica
Português
Relevância na Pesquisa
410.4591%
von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary cancer syndrome that predisposes to the development of a variety of benign and malignant tumours, especially cerebellar haemangioblastomas, retinal angiomas and clear-cell renal cell carcinomas (RCC). The etiology and manifestations are due to germline and somatic mutations in the VHL tumour suppressor gene. VHL disease is classified into type 1 and type 2, showing a clear genotype-phenotype correlation, as type 2 is associated with phaeochromocytoma and essentially caused by missense mutations. The aim of this study is to characterize the phenotype and genotype of families with VHL disease. Eighteen of twenty patients from ten unrelated families underwent genetic testing, nine of them fulfilled VHL disease criteria and one had an apparently sporadic cerebellar haemangioblastoma. Four different germline mutations in the VHL gene were identified: c.226_228delTTC (p.Phe76del); c.217C > T (p.Gln73X); IVS1-1 G > A and IVS2-1 G > C. The first three mutations were associated with type 1 disease and the last one with type 2B, which had never been identified in the germline. The transcriptional processing of a novel splice-site mutation was characterised. Three type 1 VHL families showed large deletions of the VHL gene...

‣ Rastreamento de mutações nos genes VHL, SDHB e SDHD em pacientes portadores de feocromocitoma ou também, paraganglioma esporádico; Mutation screening in the VHL, SDHB and SDHD genes in patients with sporadic pheochromocytoma and/or paraganglioma

Loureiro, Vanessa Correia
Fonte: Biblioteca Digitais de Teses e Dissertações da USP Publicador: Biblioteca Digitais de Teses e Dissertações da USP
Tipo: Dissertação de Mestrado Formato: application/pdf
Publicado em 06/03/2007 Português
Relevância na Pesquisa
414.0938%
Os feocromocitomas são tumores neuroendócrinos constituídos de células cromafins secretoras de catecolaminas e neuropeptídeos diversos, cuja manifestação clínica mais comum é a hipertensão. Doze a 24% dos tumores aparentemente esporádicos, apresentam mutações germinativas em genes até então associados a síndromes herdadas, como, RET, VHL, SDHB e SDHD. A doença de von Hippel-Lindau é causada por mutações no gene VHL. As proteínas codificadas pelos genes SDHB e SDHD fazem parte do complexo mitocondrial II e da cadeia aeróbica de transporte de elétrons. O objetivo deste projeto de pesquisa foi o rastreamento de mutações nos genes VHL, SDHB e SDHD em pacientes portadores de feocromocitoma ou, também, paraganglioma esporádicos acompanhados no Serviço de Endocrinologia do Hospital das Clínicas da FMUSP. Todos os exons dos três genes estudados foram amplificados por PCR e analisados por dHPLC. Os amplicons que apresentaram cromatogramas suspeitos ao dHPLC foram submetidos ao seqüenciamento automático. Nenhuma mutação foi encontrada no gene VHL, apenas dois polimorfismos previamente descritos no exon 1, c. -77 C>T em dois pacientes e c - 195 G>A em 58,6% do total de alelos dos pacientes estudados. No gene SDHB foram encontrados dois polimorfismos previamente descritos (c. 201-36 G>T e c.487 T>C) em quatro pacientes...

‣ Identificação e caracterização de mutações germinativas no gene VHL em famílias com a doença de von Hippel-Lindau; Identification and characterization of germline mutations in the VHL gene in families with von Hippel-Lindau disease

Gomy, Israel
Fonte: Biblioteca Digitais de Teses e Dissertações da USP Publicador: Biblioteca Digitais de Teses e Dissertações da USP
Tipo: Dissertação de Mestrado Formato: application/pdf
Publicado em 02/07/2008 Português
Relevância na Pesquisa
719.0847%
A doença de von Hippel-Lindau (VHL) é uma síndrome de câncer familial herdada de forma autossômica dominante que predispõe ao desenvolvimento de diversos tipos de neoplasias benignas e malignas. É causada por mutações germinativas e somáticas no gene VHL e tem uma incidência aproximada de um a cada 36.000 nascimentos. O gene VHL é um supressor tumoral e codifica a proteína VHL, a qual possui, entre outras funções, uma atividade ubiquitina-ligase, responsável pela poliubiquitinização e degradação proteassômica da subunidade alfa do fator induzido por hipóxia (HIF) na presença de oxigênio. As principais características da doença de VHL são: hemangioblastomas de sistema nervoso central (SNC), principalmente do cerebelo e medula espinhal; angiomas de retina e carcinoma renal de células claras. A probabilidade de desenvolver cada um desses tumores ao longo da vida é estimada em maior que 70%, podendo manifestar-se desde a infância até a fase adulta, principalmente entre a 2ª e 3ª décadas de vida. Classifica-se a doença de VHL conforme a ausência (tipo 1) ou presença de feocromocitoma (tipo 2). A doença do tipo 2 é causada, essencialmente, por mutações missense no gene VHL. As mutações podem ser grandes deleções (20%) ou pontuais (80%) do tipo missense...

‣ Molecular analysis of the Von Hippel-Lindau (VHL) gene in a family with non-syndromic pheochromocytoma: the importance of genetic testing

Cruz, Juliana B.; Fernandes, Leonardo P.S.; Clara, Sueli A.; Conde, Sandro J.; Perone, Denise; Kopp, Peter; Nogueira, Célia R.
Fonte: Sociedade Brasileira de Endocrinologia e Metabologia Publicador: Sociedade Brasileira de Endocrinologia e Metabologia
Tipo: Artigo de Revista Científica Formato: 1463-1467
Português
Relevância na Pesquisa
393.75277%
Dois pacientes índices da família analisada neste estudo foram submetidos a adrenalectomia bilateral devido a feocromocitoma. Foi, então, realizado o estudo genético dos pacientes e de sete parentes de primeiro grau. Os dois pacientes com feocromocitoma e dois outros membros assintomáticos da família apresentaram a mutação c496G>T no exon 3 do gene VHL. A família perdeu seguimento médico. Três anos após a realização da avaliação genética, a irmã dos pacientes, portadora da mutação, foi encaminhada para o nosso serviço após uma gestação complicada por pré-eclampsia. Ela referia paroxismos sugestivos de feocromocitoma, mas as metanefrinas urinárias eram negativas. Entretanto, a tomografia computadorizada de abdômen evidenciou uma massa adrenal que também se contrastou na cintilografia com metaiodobenzilguanidina (MIBG). Esse estudo mostra que a análise molecular do paciente índice pode levar à identificação de parentes assintomáticos portadores da mutação. Além disso, mesmo com as metanefrinas urinárias negativas, a identificação de uma mutação específica levou a um aumento da suspeita e detecção de feocromocitoma na irmã dos afetados pela doença.; The two index patients of the family analyzed in this study had undergone bilateral adrenalectomy for pheochromocytomas. This prompted genetic analyses of the probands and seven first-degree relatives. The two pheochromocytoma patients and two additional asymptomatic family members were found to harbor a mutation c496G>T in exon 3 of the VHL gene. The family was then lost to systematic follow-up. Three years after performing the initial genetic evaluation...

‣ Descrição clínica, imunohistoquímica e estudo dos genes VHL, SDHB, SDHC, SDHD e MAX em uma série de pacientes com feocromocitoma e paraganglioma do Distrito Federal

Moraes, Olívia Laquis de
Fonte: Universidade de Brasília Publicador: Universidade de Brasília
Tipo: Dissertação
Português
Relevância na Pesquisa
405.31844%
Dissertação (mestrado)—Universidade de Brasília, Faculdade de Ciência da Saúde, Programa de Pós-Graduação em Ciência da Saúde, 2014.; INTRODUÇÃO: Feocromocitomas (FEO) e paragangliomas (PGL) são tumores neuroendócrinos, originários de células chromafins, localizados na medula supra-renal e em tecidos extra-adrenais, respectivamente. FEO e PGL são geralmente benignos, com morbidade e mortalidade relacionadas com a produção de catecolaminas. Malignidade é relatada em aproximadamente 10%, dos casos. Estudos recentes têm mostrado que, pelo menos, 25% de todos os casos de FEO / PGL podem ter uma base genética. MÉTODOS: 17 pacientes com FEO / PGL foram incluídos. Os dados clínicos, bioquímicos e radiológicos foram obtidos dos prontuários médicos. Estudos histopatológicos e imuno-histoquímico para marcadores neuroendócrinos foram realizados. DNA genômico foi extraído e as regiões codificantes dos genes VHL, SDHB, SDHC SDHD, MAX foram amplificados e seqüenciados automaticamente. A técnica de MLPA foi utilizada para a triagem de grandes deleções / inserções. A análise do gene RET foi realizada em um paciente com evidência clínica de neoplasia endócrina múltipla do tipo 2A (MEN2A). O consentimento livre e esclarecido foi obtido de todos os pacientes. RESULTADOS: Este estudo é composto por 6 casos de PGL e 11 FEO...

‣ Preimplantation genetic diagnosis of Von Hippel-Lindau disease cancer syndrome by combined mutation and segregation analysis

Sumita,Denilce R.; Rocha,José Cláudio C.; Iaconelli Jr.,Assumpto; Borges Jr.,Edson; Pereira,Lygia V.
Fonte: Sociedade Brasileira de Genética Publicador: Sociedade Brasileira de Genética
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/03/2007 Português
Relevância na Pesquisa
404.24344%
Von Hippel-Lindau (VHL) disease is an autosomal dominant cancer syndrome, associated with the development of tumors and cysts in multiple organ systems, whose expression and age of onset are highly variable. The VHL disease tumor suppressor gene (VHL) maps to 3p25-p26 and mutations ranging from a single base change to large deletions have been detected in patients with VHL disease. We developed a single cell PCR protocol for preimplantation genetic diagnosis (PGD) of VHL disease to select unaffected embryos on the basis of the detection of the specific mutation and segregation analysis of polymorphic linked markers. Multiplex-nested PCR using single buccal cells of an affected individual were performed in order to test the accuracy and reliability of this single-cell protocol. For each locus tested, amplification efficiency was 83% to 87% and allelic drop-out rates ranged from 12% to 8%. Three VHL disease PGD cycles were performed on cells from a couple with paternal transmission of a 436delC mutation in exon 2 of the VHL gene, leading to the identification of three unaffected embryos. Independent of the mutation present, this general PGD protocol for the diagnosis of VHL disease can be used in families informative for either the D3S1038 or D3S1317 microsatellite markers.

‣ The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.

Mukhopadhyay, D; Knebelmann, B; Cohen, H T; Ananth, S; Sukhatme, V P
Fonte: PubMed Publicador: PubMed
Tipo: Artigo de Revista Científica
Publicado em /09/1997 Português
Relevância na Pesquisa
408.28426%
The von Hippel-Lindau tumor suppressor gene (VHL) has a critical role in the pathogenesis of clear-cell renal cell carcinoma (RCC), as VHL mutations have been found in both von Hippel-Lindau disease-associated and sporadic RCCs. Recent studies suggest that vascular endothelial growth factor (VEGF) mRNA is upregulated in RCC- and von Hippel-Lindau disease-associated tumors. We have therefore assessed the effect of the VHL gene product on VEGF expression. VEGF promoter-luciferase constructs were transiently cotransfected with a wild-type VHL (wt-VHL) vector in several cell lines, including 293 embryonic kidney and RCC cell lines. wt-VHL protein inhibited VEGF promoter activity in a dose-dependent manner up to 5- to 10-fold. Deletion analysis defined a 144-bp region of the VEGF promoter necessary for VHL repression. This VHL-responsive element is GC rich and specifically binds the transcription factor Sp1 in crude nuclear extracts. In Drosophila cells, cotransfected VHL represses Sp1-mediated activation but not basal activity of the VEGF promoter. We next demonstrated in coimmunoprecipitates that VHL and Sp1 were part of the same complex and, by using a glutathione-S-transferase-VHL fusion protein and purified Sp1, that VHL and Sp1 directly interact. Furthermore...

‣ VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail▿ †

Evans, Andrew J.; Russell, Ryan C.; Roche, Olga; Burry, T. Nadine; Fish, Jason E.; Chow, Vinca W. K.; Kim, William Y.; Saravanan, Arthy; Maynard, Mindy A.; Gervais, Michelle L.; Sufan, Roxana I.; Roberts, Andrew M.; Wilson, Leigh A.; Betten, Mark; Vandewa
Fonte: American Society for Microbiology Publicador: American Society for Microbiology
Tipo: Artigo de Revista Científica
Português
Relevância na Pesquisa
401.44137%
The product of the von Hippel-Lindau gene (VHL) acts as the substrate-recognition component of an E3 ubiquitin ligase complex that ubiquitylates the catalytic α subunit of hypoxia-inducible factor (HIF) for oxygen-dependent destruction. Although emerging evidence supports the notion that deregulated accumulation of HIF upon the loss of VHL is crucial for the development of clear-cell renal cell carcinoma (CC-RCC), the molecular events downstream of HIF governing renal oncogenesis remain unclear. Here, we show that the expression of a homophilic adhesion molecule, E-cadherin, a major constituent of epithelial cell junctions whose loss is associated with the progression of epithelial cancers, is significantly down-regulated in primary CC-RCC and CC-RCC cell lines devoid of VHL. Reintroduction of wild-type VHL in CC-RCC (VHL−/−) cells markedly reduced the expression of E2 box-dependent E-cadherin-specific transcriptional repressors Snail and SIP1 and concomitantly restored E-cadherin expression. RNA interference-mediated knockdown of HIFα in CC-RCC (VHL−/−) cells likewise increased E-cadherin expression, while functional hypoxia or expression of VHL mutants incapable of promoting HIFα degradation attenuated E-cadherin expression...

‣ Expression of the Von Hippel-Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis.

Kessler, P. M.; Vasavada, S. P.; Rackley, R. R.; Stackhouse, T.; Duh, F. M.; Latif, F.; Lerman, M. I.; Zbar, B.; Williams, B. R.
Fonte: The Feinstein Institute for Medical Research Publicador: The Feinstein Institute for Medical Research
Tipo: Artigo de Revista Científica
Publicado em /05/1995 Português
Relevância na Pesquisa
412.70547%
BACKGROUND: Von Hippel-Lindau (VHL) disease is a familial cancer syndrome that has a dominant inherited pattern which predisposes affected individuals to a variety of tumours. The most frequent tumors are hemangioblastomas of the central nervous system and retina, renal cell carcinoma (RCC), and pheochromocytoma. The recent identification and characterization of the VHL gene on human chromosome 3p and mutational analyses confirms the VHL gene functions as a classical tumor suppressor. Not only are mutations in this gene responsible for the VHL syndrome, but mutations are also very frequent in sporadic RCC. MATERIALS AND METHODS: VHL expression in human kidney and during embryogenesis, was analyzed by in situ mRNA hybridization with 35S-labeled antisense VHL probes, derived from human and mouse cDNAs, on cryosections of human fetal kidney and paraffin sections of murine embryos. RESULTS: In human fetal kidney, there was enhanced expression of VHL within the epithelial lining of the proximal tubules. During embryogenesis, VHL expression was ubiquitous in all three germ cell layers and their derivatives. Expression occurred in the cerebral cortex, midbrain, cerebellum, retina, spinal cord, and postganglionic cell bodies. All organs of the thoracic and abdominal cavities expressed VHL...

‣ VHL Inactivation in Renal Cell Carcinoma: Implications for Diagnosis, Prognosis, and Treatment

Rathmell, W. Kimryn; Chen, Shufen
Fonte: PubMed Publicador: PubMed
Tipo: Artigo de Revista Científica
Publicado em /01/2008 Português
Relevância na Pesquisa
385.85527%
Clear cell renal cell carcinoma (ccRCC) provides a tumor paradigm for the integration of genetics, molecular biology, therapeutic target validation, and the introduction of high impact treatment strategies. Most cases of sporadic as well as familial ccRCC acquire somatic inactivating mutations of the von Hippel-Lindau tumor suppressor gene, VHL. pVHL, VHL gene product and a protein member of the E3 ubiquitin ligase family, acts in normal cells to direct the degradation and clearance of the hypoxia inducible factor (HIFα) transcription factor family, such that in its absence, as in ccRCC, the HIF proteins stabilize, accumulate to supraphysiologic levels, and activate the transcription of genes such as vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF), which contributes substantially to the physiology of the tumor, and has been assessed indirectly as a prognostic factor. Molecularly targeted therapy blocking components of this pathway has been successfully introduced to the clinic with a substantive impact on clinical parameters of RCC. This review will examine the regulation of these molecular pathways in RCC and discuss the impact on the clinical management of patients with RCC.

‣ The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy

Clark, Peter E.
Fonte: PubMed Publicador: PubMed
Tipo: Artigo de Revista Científica
Português
Relevância na Pesquisa
372.2258%
The basic biology underlying the development of clear-cell renal cell carcinoma (ccRCC) is critically dependent on the von Hippel–Lindau gene (VHL), whose protein product is important in the cell’s normal response to hypoxia. Aberrations in VHL’s function, either through mutation or promoter hypermethylation, lead to accumulation of the transcriptional regulatory molecule, hypoxia-inducible factor alpha (HIFα). HIFα can then dimerize with HIFβ and translocate to the nucleus, where it will transcriptionally upregulate a series of hypoxia-responsive genes, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and others. Binding of these ligands to their cognate receptors activates a series of kinase–dependent signaling pathways, including the RAF–MEK–ERK and phosphatidylinositol-3 kinase–AKT–mTOR pathways. Targeted agents developed and now approved for use in advanced ccRCC include humanized monoclonal antibodies against VEGF, small-molecule tyrosine kinase inhibitors, and inhibitors of mTOR. Understanding the biology of ccRCC is critical in understanding the current therapy for the disease and in developing novel therapeutics in the future. This review will provide an overview of the genetics of ccRCC...

‣ VHL-regulated miR-204 Suppresses Tumor Growth through Inhibition of LC3B-mediated Autophagy in Renal Clear Cell Carcinoma

Mikhaylova, Olga; Stratton, Yiwen; Hall, Daniel; Kellner, Emily; Ehmer, Birgit; Drew, Angela F.; Gallo, Catherine A.; Plas, David R.; Biesiada, Jacek; Meller, Jarek; Czyzyk-Krzeska, Maria F.
Fonte: PubMed Publicador: PubMed
Tipo: Artigo de Revista Científica
Publicado em 17/04/2012 Português
Relevância na Pesquisa
391.546%
The von Hippel-Lindau tumor-suppressor gene (VHL) is lost in most clear cell renal cell carcinomas (ccRCC). Here, using human ccRCC specimens, VHL-deficient cells, and xenograft models, we show that miR-204 is a VHL-regulated tumor suppressor acting by inhibiting macroautophagy, with MAP1LC3B (LC3B) as a direct and functional target. Importantly, higher tumor grade of human ccRCC was correlated with a concomitant decrease in miR-204 and increase in LC3B levels, indicating that LC3B-mediated macroautophagy is necessary for RCC progression. VHL, in addition to inducing endogenous miR-204, triggered the expression of LC3C, an HIF-regulated LC3B paralog, that suppressed tumor growth. These data reveal a function of VHL as a tumor suppressing regulator of autophagic programs.

‣ Complex cellular functions of the von Hippel–Lindau tumor suppressor gene: insights from model organisms

Hsu, T
Fonte: PubMed Publicador: PubMed
Tipo: Artigo de Revista Científica
Português
Relevância na Pesquisa
400.25547%
The von Hippel–Lindau tumor suppressor gene (VHL) has attracted intensive interest not only because its mutations predispose carriers to devastating tumors, but also because it is involved in oxygen sensing under physiological conditions. VHL loss-of-function mutations result in organ-specific tumors, such as hemangioblastoma of the central nervous system and renal cell carcinoma, both untreatable with conventional chemotherapies. The VHL protein is best known as an E3 ubiquitin ligase that targets hypoxia-inducible factor-α (HIF-α), but many diverse, non-canonical cellular functions have also been assigned to VHL, mainly based on studies in cell culture systems. As such, although the HIF-dependent role of VHL is critical, the full spectrum of pathophysiological functions of VHL is still unresolved. Such understanding requires careful cross-referencing with physiologically relevant experimental models. Studies in model systems, such as Caenorhabditis elegans, Drosophila, zebrafish and mouse have provided critical in vivo confirmation of the VHL–HIF pathway, and verification of potentially important cellular functions including microtubule stabilization and epithelial morphogenesis. More recently, animal models have also suggested systemic roles of VHL in hematopoiesis...

‣ Systemic VHL gene functions and the VHL disease

Bader, Hannah L.; Hsu, Tien
Fonte: PubMed Publicador: PubMed
Tipo: Artigo de Revista Científica
Português
Relevância na Pesquisa
403.22992%
The von Hippel-Lindau tumor suppressor gene (VHL) is best known as an E3 ubiquitin ligase that negatively regulates the hypoxia inducible factor (HIF). VHL mutations are the genetic defects underlying several human diseases including polycythemia, familial VHL tumor syndrome and sporadic renal cell carcinoma. VHL mutations can lead to cell-autonomous phenotypes in the tumor cells. However, non-tumor cell-autonomous functions of VHL have also been noted. VHL tumor-derived cytokines can promote inflammation and induce mobilization of endothelial progenitor cells. Up-regulation of HIF caused by VHL loss-of-function mutants, including heterozygotes, has been shown to increase the activities of hematopoietic stem cells, endothelial cells and myeloid cells. As such, systemic functions of VHL likely play important roles in the development of VHL disease.

‣ Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions

Jung, Youn-Sang; Lee, Su-Jin; Yoon, Min-Ho; Ha, Nam Chul; Park, Bum-Joon
Fonte: Landes Bioscience Publicador: Landes Bioscience
Tipo: Artigo de Revista Científica
Publicado em 01/12/2012 Português
Relevância na Pesquisa
393.43094%
The Von Hippel-Lindau gene (VHL) is frequently deleted or mutated in human renal cell carcinoma (RCC) at the early stage. According to the well-established theory, pVHL acts as a tumor suppressor through its E3 ligase activity, which targets hypoxia-inducing factor-1α (HIF-1α). However, the elevated expression of HIF-1α did not promote cell proliferation, indicating that there would be another target, which could promote cell proliferation at the early cancer stage of RCC. In this study, we show that estrogen receptor-α (ER-α) is a novel proteasomal degradation target of the pVHL E3 ligase. Indeed, the overexpression of VHL suppresses exo- and endogenous ER-α expression, whereas si-pVHL can increase ER-α expression. The negative regulation of pVHL on ER-α expression is achieved by its E3 ligase activity. Thus, pVHL can promote the ER-α ubiquitinylation. In addition, we revealed that ER-α and HIF-1α are competitive substrates of pVHL. Thus, under normal conditions, ER-α overexpression can increase the transcription factor activity of HIF-1α. Under the hypoxic condition, where HIF-1α is not a suitable target of pVHL, ER-α is more rapidly degraded by pVHL. However, in VHL-deficient cells, the expression of ER-α and HIF-1α is retained...

‣ Loss of VHL promotes progerin expression, leading to impaired p14/ARF function and suppression of p53 activity

Jung, Youn-Sang; Lee, Su-Jin; Lee, Sun-Hye; Chung, Ji-Yun; Jung, Youn Jin; Hwang, Sang Hyun; Ha, Nam-Chul; Park, Bum-Joon
Fonte: Landes Bioscience Publicador: Landes Bioscience
Tipo: Artigo de Revista Científica
Português
Relevância na Pesquisa
377.57516%
Renal cell carcinomas (RCCs) are frequently occurring genitourinary malignancies in the aged population. A morphological characteristic of RCCs is an irregular nuclear shape, which is used to index cancer grades. Other features of RCCs include the genetic inactivation of the von Hippel-Lindau gene, VHL, and p53 genetic-independent inactivation. An aberrant nuclear shape or p53 suppression has not yet been demonstrated. We examined the effect of progerin (an altered splicing product of the LMNA gene linked to Hutchinson Gilford progeria syndrome; HGPS) on the nuclear deformation of RCCs in comparison to that of HGPS cells. In this study, we showed that progerin was suppressed by pVHL and was responsible for nuclear irregularities as well as p53 inactivation. Thus, progerin suppression can ameliorate nuclear abnormalities and reactivate p53 in response to genotoxic addition. Furthermore, we found that progerin was a target of pVHL E3 ligase and suppressed p53 activity by p14/ARF inhibition. Our findings indicate that the elevated expression of progerin in RCCs results from the loss of pVHL and leads to p53 inactivation through p14/ARF suppression. Interestingly, we showed that progerin was expressed in human leukemia and primary cell lines...

‣ The Apoptosis Repressor with a CARD Domain (ARC) Gene Is a Direct Hypoxia-Inducible Factor 1 Target Gene and Promotes Survival and Proliferation of VHL-Deficient Renal Cancer Cells

Razorenova, Olga V.; Castellini, Laura; Colavitti, Renata; Edgington, Laura E.; Nicolau, Monica; Huang, Xin; Bedogni, Barbara; Mills, Edward M.; Bogyo, Matthew; Giaccia, Amato J.
Fonte: American Society for Microbiology Publicador: American Society for Microbiology
Tipo: Artigo de Revista Científica
Publicado em /02/2014 Português
Relevância na Pesquisa
390.38168%
The induction of hypoxia-inducible factors (HIFs) is essential for the adaptation of tumor cells to a low-oxygen environment. We found that the expression of the apoptosis inhibitor ARC (apoptosis repressor with a CARD domain) was induced by hypoxia in a variety of cancer cell types, and its induction is primarily HIF1 dependent. Chromatin immunoprecipitation (ChIP) and reporter assays also indicate that the ARC gene is regulated by direct binding of HIF1 to a hypoxia response element (HRE) located at bp −190 upstream of the transcription start site. HIFs play an essential role in the pathogenesis of renal cell carcinoma (RCC) under normoxic conditions, through the loss of the Von Hippel-Lindau gene (VHL). Accordingly, our results show that ARC is not expressed in normal renal tissue but is highly expressed in 65% of RCC tumors, which also express high levels of carbonic anhydrase IX (CAIX), a HIF1-dependent protein. Compared to controls, ARC-deficient RCCs exhibited decreased colony formation and increased apoptosis in vitro. In addition, loss of ARC resulted in a dramatic reduction of RCC tumor growth in SCID mice in vivo. Thus, HIF-mediated increased expression of ARC in RCC can explain how loss of VHL can promote survival early in tumor formation.

‣ Inactivation of Vhl in Osteochondral Progenitor Cells Causes High Bone Mass Phenotype and Protects Against Age-Related Bone Loss in Adult Mice

Weng, Tujun; Xie, Yangli; Huang, Junlan; Luo, Fengtao; Yi, Lingxian; He, Qifen; Chen, Di; Chen, Lin
Fonte: PubMed Publicador: PubMed
Tipo: Artigo de Revista Científica
Publicado em /04/2014 Português
Relevância na Pesquisa
396.092%
Previous studies have shown that disruption of von Hippel–Lindau gene (Vhl) coincides with activation of hypoxia-inducible factor α (HIFα) signaling in bone cells and plays an important role in bone development, homeostasis, and regeneration. It is known that activation of HIF1α signaling in mature osteoblasts is central to the coupling between angiogenesis and bone formation. However, the precise mechanisms responsible for the coupling between skeletal angiogenesis and osteogenesis during bone remodeling are only partially elucidated. To evaluate the role of Vhl in bone homeostasis and the coupling between vascular physiology and bone, we generated mice lacking Vhl in osteochondral progenitor cells (referred to as Vhl cKO mice) at postnatal and adult stages in a tamoxifen-inducible manner and changes in skeletal morphology were assessed by micro–computed tomography (µCT), histology, and bone histomorphometry. We found that mice with inactivation of Vhl in osteochondral progenitor cells at the postnatal stage largely phenocopied that of mice lacking Vhl in mature osteoblasts, developing striking and progressive accumulation of cancellous bone with increased microvascular density and bone formation. These were accompanied with a significant increase in osteoblast proliferation...

‣ Mutationsanalyse des VHL-Tumorsuppressorgens vor dem Hintergrund der erblichen VHL-Erkrankung und Karzinogenexposition beim sporadischen Nierenzellkarzinom; Mutation analysis of the VHL-tumor suppressor gene with respect to the hereditary VHL-disease and carcinogen-induced sporadic renal cell carcinoma

Klein, Bettina
Fonte: Universität Tübingen Publicador: Universität Tübingen
Tipo: Dissertation; info:eu-repo/semantics/doctoralThesis
Português
Relevância na Pesquisa
515.81562%
Das von Hippel-Lindau-Tumorsuppressorgen (VHL) ist ursächlich an der Entstehung der erblichen von Hippel-Lindau-Erkrankung (VHL), einem Multi-Tumor-Syndrom beteiligt. Mutationen in diesem Gen können die Funktion des Genprodukts (pVHL) modulieren, dessen Rolle beim kontrollierten Proteinabbau im Proteasom am besten erforscht ist. Für die Etablierung von aussagefähigen Genotyp-Phänotyp-Korrelationen sind zunehmend moderne Verfahren zur kostengünstigen, schnellen und verlässlichen VHL-Mutationsdetektion in Blut-DNA gefragt, wie z.B. DHPLC- und Sequenzieranalysen. Aus diesem Grund wurde im ersten Teil der vorliegenden Arbeit eine PCR- und DHPLC-basierte Nachweismethode für bereits bekannte VHL-Keimbahnmutationen etabliert. Diese Methode wurde anschließend für den Nachweis von Mutationen bei VHL-Verdachtspatienten angewandt. Im Rahmen der Aufklärung der komplexen Genotyp-Phänotyp-Zusammenhänge beim VHL-Syndrom konnten zwei kosegregierende VHL-Mutationen, 454 C>T (Pro81Ser) und 775 C>G (Leu188Val), dem VHL2C-Phänotyp zugeordnet werden. Zunächst war davon ausgegangen worden, dass dieser minimale VHL-Phänotyp durch eine Leu188Val-Mutation in der alpha-Domäne des pVHL hervorgerufen wird und so die Interaktion mit dem Protein Elongin C stört. In dieser Arbeit wurde erstmalig gezeigt...

‣ Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes.

Clifford, S. C.; Czapla, K.; Richards, F. M.; O'Donoghue, D. J.; Maher, E. R.
Fonte: Nature Publishing Group Publicador: Nature Publishing Group
Tipo: Artigo de Revista Científica
Publicado em /05/1998 Português
Relevância na Pesquisa
403.3067%
Hepatocyte growth factor (HGF/SF) is a potent renal proximal tubular cell (PTEC) mitogen involved in renal development. HGF/SF is the functional ligand for the c-met proto-oncogene, and germline c-met mutations are associated with familial papillary renal cell carcinoma. Somatic von Hippel-Lindau disease tumour-suppressor gene (VHL) mutations are frequently detected in sporadic clear cell renal cell carcinomas (RCC), and germline VHL mutations are the commonest cause of familial clear cell RCC. pVHL binds to the positive regulatory components of the trimeric elongin (SIII) complex (elongins B and C) and has been observed to deregulate expression of the vascular endothelial growth factor (VEGF) gene. HGF/SF has similarly been reported to up-regulate expression of the VEGF gene in non-renal experimental systems. To investigate the mechanism of HGF/SF action in PTECs and, specifically, to examine potential interactions between the HGF/c-met and the VHL-mediated pathways for renal tubular growth control, we have isolated untransformed PTECs from normal kidneys, developed conditions for their culture in vitro and used these cells to investigate changes in mRNA levels of the VHL, elongin A, B and C, VEGF, c-myc, c-fos and c-met genes after HGF/SF exposure. Significant elevations in the mRNA levels of VEGF...